EUVIMEDEUVIMED entdecken
Crossref

Frequency matters: comparison of drug resistance mutation detection by Sanger and next-generation sequencing in HIV-1

Suraj Balakrishna, Tom Loosli, Maryam Zaheri, Paul Frischknecht, Michael Huber, Katharina Kusejko iD, Sabine Yerly, Karoline Leuzinger, Matthieu Perreau, Alban Ramette iD, Chris Wymant iD, Christophe Fraser und 12 weitere

Journal of Antimicrobial Chemotherapy · 02.03.2023 · 78 (3) · 656-664

DOI: 10.1093/jac/dkac430 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 04.02.2023. Verfasst von Suraj Balakrishna und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: HIV-1, HIV Infections, HIV Seropositivity, Anti-HIV Agents. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Swiss National Science Foundation, SHCS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Next-generation sequencing (NGS) is gradually replacing Sanger sequencing (SS) as the primary method for HIV genotypic resistance testing. However, there are limited systematic data on comparability of these methods in a clinical setting for the presence of low-abundance drug resistance mutations (DRMs) and their dependency on the variant-calling thresholds.

Methods

To compare the HIV-DRMs detected by SS and NGS, we included participants enrolled in the Swiss HIV Cohort Study (SHCS) with SS and NGS sequences available with sample collection dates ≤7 days apart. We tested for the presence of HIV-DRMs and compared the agreement between SS and NGS at different variant-calling thresholds.

Results

We included 594 pairs of SS and NGS from 527 SHCS participants. Males accounted for 80.5% of the participants, 76.3% were ART naive at sample collection and 78.1% of the sequences were subtype B. Overall, we observed a good agreement (Cohen’s kappa >0.80) for HIV-DRMs for variant-calling thresholds ≥5%. We observed an increase in low-abundance HIV-DRMs detected at lower thresholds [28/417 (6.7%) at 10%–25% to 293/812 (36.1%) at 1%–2% threshold]. However, such low-abundance HIV-DRMs were overrepresented in ART-naive participants and were in most cases not detected in previously sampled sequences suggesting high sequencing error for thresholds <3%.

Conclusions

We found high concordance between SS and NGS but also a substantial number of low-abundance HIV-DRMs detected only by NGS at lower variant-calling thresholds. Our findings suggest that a substantial fraction of the low-abundance HIV-DRMs detected at thresholds <3% may represent sequencing errors and hence should not be overinterpreted in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1HIV InfectionsHIV SeropositivityAnti-HIV AgentsMaleHumansCohort StudiesDrug Resistance, ViralViral LoadMutationHigh-Throughput Nucleotide SequencingGenotype

Substanzen

Anti-HIV Agents

Autor:innen und Institutionen

  • Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • Swiss National Center for Retroviruses, University of Zurich, Zurich, Switzerland.
  • Laboratory of Virology, University Hospital Geneva, University of Geneva, Geneva, Switzerland.
  • Clinical Virology Division, Laboratory Medicine, University Hospital Basel, Basel, Switzerland.
  • Division of Immunology and Allergy, University Hospital Lausanne, University of Lausanne, Lausanne, Switzerland.

ORCID-Profile: Katharina Kusejko, Alban Ramette, Chris Wymant, Hans H Hirsch, Matthias Cavassini, Huldrych F Günthard, Roger D Kouyos

Förderung

  • Swiss National Science Foundation
  • SHCS

Zitieren

APA

Balakrishna, S., Loosli, T., Zaheri, M., Frischknecht, P., Huber, M., Kusejko, K., Yerly, S., Leuzinger, K., Perreau, M., Ramette, A., Wymant, C., Fraser, C., Kellam, P., Gall, A., Hirsch, H. H., Stoeckle, M., Rauch, A., Cavassini, M., Bernasconi, E., …, & Kouyos, R. D. (2023). Frequency matters: comparison of drug resistance mutation detection by Sanger and next-generation sequencing in HIV-1. Journal of Antimicrobial Chemotherapy, 78(3), 656-664. https://doi.org/10.1093/jac/dkac430

Vancouver

Balakrishna S, Loosli T, Zaheri M, Frischknecht P, Huber M, Kusejko K, et al. Frequency matters: comparison of drug resistance mutation detection by Sanger and next-generation sequencing in HIV-1. Journal of Antimicrobial Chemotherapy. 2023;78(3):656-664. doi:10.1093/jac/dkac430

BibTeX
@article{Balakrishna2023,
  author = {Balakrishna, Suraj and Loosli, Tom and Zaheri, Maryam and Frischknecht, Paul and Huber, Michael and Kusejko, Katharina and Yerly, Sabine and Leuzinger, Karoline and Perreau, Matthieu and Ramette, Alban and Wymant, Chris and Fraser, Christophe and Kellam, Paul and Gall, Astrid and Hirsch, Hans H and Stoeckle, Marcel and Rauch, Andri and Cavassini, Matthias and Bernasconi, Enos and Notter, Julia and Calmy, Alexandra and Günthard, Huldrych F and Metzner, Karin J and Kouyos, Roger D},
  title = {Frequency matters: comparison of drug resistance mutation detection by Sanger and next-generation sequencing in HIV-1},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2023},
  volume = {78},
  number = {3},
  pages = {656--664},
  doi = {10.1093/jac/dkac430}
}
Kostenlos starten →